• 作者：Manuel Luque-Ramí ; rez^a ; ^{manuel.luque@salud.madrid.org} ; Á ; gata Carreñ ; o^b ; Cristina Á ; lvarez Escolá ; ^c ; Carlos del Pozo Picó ; ^d ; Cé ; sar Varela da Costa^e ; Carmen Fajardo Montañ ; ana^f ; Montserrat Gilabert^g ; Susan Webb^h ; Grupo Españ ; ol del estudio OASIS^&loz ;
• 关键词：Acromegalia ; Prá ; ctica cl&iacute ; nica ; Eficacia terapé ; utica ; Neurocirug&iacute ; a ; Aná ; logos de somatostatina
• 刊名：Endocrinolog铆a y Nutrici贸n
• 出版年：2011
• 期刊代码：pca151_15750922
• 类别：med
• 出版时间：November 2011
• 卷：58
• 期：9
• 页码：478-486
• 文件大小：280 K

class="h4">Background and objectives

The reported efficacy of treatments for acromegaly varies depending on reference centers and national registries. The aim of this study was to describe clinical management of this disease and to assess the efficacy of treatments used in standard clinical practice.

class="h4">Material and methods

An epidemiological, observational, longitudinal, multicenter study was performed in adult patients with newly diagnosed acromegaly (n = 74) seen by 38 Spanish endocrinologists who collected during routine clinic visits data on disease treatment and control during 2 years of follow-up.

class="h4">Results

Pituitary surgery and treatment with somatostatin analogs were the first choice therapies in 76%and 24%of patients respectively, with no differences related to tumor size. Surgery achieved disease control in 27%of operated patients. After surgery failure, the preferred therapeutic option were somatostatin analogs, which normalized insulin-like growth factor-1(IGF-I) in 52%of patients and achieved disease control criteria in more than 40%of patients. At the end of follow-up, normal IGF-I levels were found in 63%and 53%of patients with microadenomas and macroadenomas respectively. Only 19%of patients with macroadenoma met disease control criteria without requiring drug treatment, which was required by 85%of them at some time during follow-up.

class="h4">Conclusions

Surgery is the preferred initial treatment for patients with acromegaly, regardless of tumor size. Treatment efficacy in actual clinical practice is far from the success rates reported by reference centers.